,51 Of note, due to the limitations of the NSG model, our work does not address previously reported indirect antitumor effects of iNKT cell–based immunotherapy, including depletion of CD1d-expressing immunosuppressive, tumor-associated myeloid cells, and activation of antitumor T- and NK-cell responses.30 The gene discussed is CD1D; the disease is neoplasm.